Efficacy and safety of [225ac]ac-psma-617 augmented [177lu]lu-psma-617 radioligand therapy in patients with highly advanced mcrpc with poor prognosis
Rosar F, Krause J, Bartholomä M, Maus S, Stemler T, Hierlmeier I, Linxweiler J, Ezziddin S, Khreish F (2020)
Publication Type: Journal article
Publication year: 2020
Journal
Book Volume: 13
Article Number: 722
Journal Issue: 5
DOI: 10.3390/pharmaceutics13050722
Abstract
The use of225Ac in prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT), either as monotherapy or in combination with177Lu, is a promising therapy approach in patients with metastatic castration-resistant prostate carcinoma (mCRPC). In this study, we report the efficacy and safety of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in177Lu-naive mCRPC patients (n = 15) with poor prognosis (presence of visceral metastases, high total tumor burden with diffuse bone metastases or a short PSA doubling time of <2 months). Biochemical (by PSA serum value) and molecular imaging response (by [68Ga]Ga-PSMA-11 PET/CT) was assessed after two cycles of [177Lu]Lu-PSMA-617 RLT, with at least one [225Ac]Ac-PSMA-617 augmentation. In addition, PSA-based progression-free survival (PSA-PFS), overall survival (OS) and toxicity (according to CTCAE) were analyzed. We observed a biochemical-and molecular imaging-based partial remission in 53.3% (8/15) and 66.7% (10/15) of patients, respectively. The median PSA-PFS and OS was 9.1 and 14.8 months, respectively. No serious acute adverse events were recorded. Two out of fifteen patients experienced grade 3 anemia. No other grade 3/4 toxicities were observed. RLT-related xerostomia (grade 1/2) was recorded in 2/15 patients. Our data showed a high clinical efficacy with a favorable side effects profile of [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in this highly challenging patient cohort.
Involved external institutions
Germany (DE)How to cite
APA:
Rosar, F., Krause, J., Bartholomä, M., Maus, S., Stemler, T., Hierlmeier, I.,... Khreish, F. (2020). Efficacy and safety of [225ac]ac-psma-617 augmented [177lu]lu-psma-617 radioligand therapy in patients with highly advanced mcrpc with poor prognosis. Pharmaceutics, 13(5). https://doi.org/10.3390/pharmaceutics13050722
MLA:
Rosar, Florian, et al. "Efficacy and safety of [225ac]ac-psma-617 augmented [177lu]lu-psma-617 radioligand therapy in patients with highly advanced mcrpc with poor prognosis." Pharmaceutics 13.5 (2020).
BibTeX: Download